High prevalence of PD-L1 positivity has also been reported in MSI-H GC as well as the high infiltration of TILs.18 Due to these properties, MSI-H GCs are expected to respond to immune checkpoint blockade therapy, especially to the anti-PD-1/PD-L1 therapy. The gene discussed is CD274; the disease is gastric cancer.